Corpus ID: 8087044

XP-828 L in the Treatment of Mild-to-Moderate Psoriasis : A Randomized , Double-blind , Placebo-controlled Study

  title={XP-828 L in the Treatment of Mild-to-Moderate Psoriasis : A Randomized , Double-blind , Placebo-controlled Study},
  author={Yves Poulin and Robert Bissonnette and Christina Juneau and Kim Cantin and R{\'e}jean Drouin and Patrice E. Poubelle},
Advitech is the developer of XP-828L. Abstract Background: XP-828L, a protein extract obtained from sweet whey, has demonstrated potential benefit for the treatment of mild to moderate psoriasis in an open-label study. Objective: To study in a randomized, double-blind, placebo-controlled study the safety and efficacy of XP-828L in the treatment of mild to moderate psoriasis. Design: XP-828L 5 g/d (group A, n=42) or placebo (group B, n=42) was given orally for 56 days followed by XP-828L 5 g/d… Expand
2 Citations

Figures and Tables from this paper

Chinese herbal medicine for psoriasis: evaluation of clinical evidence and investigation of the anti-psoriatic effects of specific Chinese medicinal herbs
Psoriasis is a chronic and recurrent skin disease that affects 1-5% of the population and around half of psoriasis patients use compleme treatments, which can have significant side effects. Expand
Strategic Analysis of Indian Nutraceutical Regulatory Scenario through Market Research
This study has revealed that, child Nutraceutical Products are in high demand followed by Nutraceuticals for Pregnant / Lactating Mothers and Weight Gain Products, therefore, it is very important to regulate the manufacturing, labeling, and advertisement of the Nutraceutical products targeted to Children, Preg pregnant and lactating mothers. Expand


Safety and Efficacy of a Milk-derived Extract in the Treatment of Plaque Psoriasis:An Open-label Study
XP-828L may improve psoriasis in patients with mild-to-moderate psor dermatitis in an open-label study performed to determine the efficacy, tolerability and safety of XP-8 28L in the treatment of plaque psOriasis. Expand
A double-blind placebo controlled trial of Efamol Marine on skin and joint symptoms of psoriatic arthritis.
It is suggested that Efamol Marine may alter prostaglandin metabolism in patients with PsA, although it did not produce a clinical improvement and did not allow reduction in NSAID requirement. Expand
Double‐blind, placebo‐controlled study to evaluate the efficacy of fish oil and low‐dose UVB in the treatment of psoriasis
The apparent safety and general health‐promoting features of fish oil could provide an ideal adjunctive therapy for psoriasis. Expand
The Role of Fish Oil in Psoriasis
The authors attempt to put the role of fish oil in the therapy of psoriasis into perspective and discuss the efficacy ofFish oil when used alone versus in combination therapy and using survival analysis methods. Expand
Omega-3 fatty acid-based lipid infusion in patients with chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, multicenter trial.
Intravenous omega-3-fatty acid administration is effective in the treatment of chronic plaque-type psoriasis and may be related to changes in inflammatory eicosanoid generation. Expand
Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.
Treatment with alefacept for 12 weeks is associated with improvement in chronic plaque psoriasis; some patients have a sustained clinical response after the cessation of treatment, suggesting that they have a role in the pathogenesis of Psoriasis. Expand
Psoriasis: current perspectives with an emphasis on treatment.
Because the regimens involved in systemic and phototherapy are complex and require frequent dose adjustments and specialized equipment, the patient should be referred to a dermatologist when topical therapy is not effective. Expand
Effect of dietary supplementation with very-long-chain n-3 fatty acids in patients with psoriasis.
Dietary supplementation with very-long-chain n-3 fatty acids was no better than corn-oil supplementation in treating psoriasis, and there was no significant difference in clinical manifestations between the groups. Expand
Polymeric nutrition as the primary therapy in children with small bowel Crohn's disease.
In an uncontrolled descriptive study, a polymeric (whole protein) diet is a therapeutic option for small bowel Crohn's disease in children with clinical and biochemical remission, with an improved endoscopic appearance and a reduction of mucosal inflammation in the terminal ileum. Expand
Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis
The reversal of several molecular markers of epidermal dysfunction was associated with a marked reduction in intraepidermal CD3+ and CD8+ T cells, suggesting a primary immunological basis for this widespread disorder. Expand